Navigation Links
Helix BioPharma announces $16.9 million private placement of common shares
Date:12/17/2007

AURORA, Ontario, Dec. 17 /PRNewswire-FirstCall/ - Helix BioPharma Corp. (TSX, FSE: "HBP") today announced that it has received subscriptions for the purchase, by way of private placement, of a total of 10,040,000 common shares at $1.68 per share, for gross proceeds totaling CDN$16,867,200. Proceeds from the placement will be used for working capital, primarily to fund the Company's research and development initiatives.

The Company expects to close the private placement within the next ten days.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its Topical Interferon Alpha-2b and its novel L-DOS47 new drug candidate. Helix is listed on the TSX under the symbol "HBP" and quoted on the Frankfurt, Berlin, Munich and Stuttgart Stock Exchanges under the same symbol.

The Toronto Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this News Release. This News Release contains forward-looking statements regarding a proposed private placement and the Company's activities, which statements can be identified by the words "will", "anticipates", and "developing". Actual results or events could differ materially from these forward-looking statements due to numerous factors, including without limitation, the risk that the proposed placement may not close as anticipated or at all, research & development risks, Helix's need for additional future capital, the risk of unanticipated expenses, and possible changes in business strategy or plans. These and other risks and uncertainties are contained in Helix's latest Annual Information Form at http://www.sedar.com'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
10. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
11. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2008)...the Practical Implementation of ... October 13 /- After the successful,s...ram at the beginning of,the year, Ziehm Imaging, p...consequently expanding its training offer. The Zie...ional standards, in order to keep its,partners up ...
(Date:10/13/2008)... 13 /-,Following fulfillmen...,completed the acquisition* of all outstanding sha...escription optical equipment., Satisloh designs a...ing,machines, as well as consumables, for prescrip...evenue in 2007 and employs more than 400 people,ar...
(Date:10/11/2008)...ire/ -- MedImmune announced today it,will present ...cs (AAP),2008 National Conference & Exhibition tha...to the prevention of respiratory syncytial virus (...on among preterm infants., "As we gain data that ...reterm babies, the benefits of preventive care bec...
(Date:10/10/2008)...swire-FirstCall/ -- Neurobiological,Technologies, ... will hold a,conference call on Monday, October 13...) Phase 3 Trial Program for acute ischemic stroke....nt and chief executive,officer and Warren W. Wasie...October 13, 2008 -- Time: 1:00 p.m. (ET), 12:00 ...
Breaking Biology Technology:Ziehm Imaging Extends its Training Offer 2Ziehm Imaging Extends its Training Offer 3Ziehm Imaging Extends its Training Offer 4MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease 2MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease 3MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease 4MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease 5Neurobiological Technologies Announces Update Call on Viprinex (TM) Phase 3 Trial Program 2
...bout the latest outrages in the CEO suite, let me ...jority of top executives are honest and good peopl... success. And that the CEO,s I will be talking abo...g. Still, these are people who work the system to ... that can easily lead even the most successful com...
... promote competition. It was supposed to create ce... better infrastructure. Ten years later, can we sa...s wasted? Did we ever really achieve the open comp...esday is the tenth anniversary of the act. Especia... these controversies surrounding competition and t...
...d Software, a Milwaukee-based startup that runs an...eships around the universe. , , Official screensh...Technology Innovation Center that houses many more...s like Shining Brow Software and Niceware Inter...t Vendetta Online , came about in part because of...
...ank of Green Bay have joined a new $125 venture fu..., Tonka Bay Equity Partners of Minnetonka, Minnes...s from around the country and some individual inve...sinesses in manufacturing and business services. ,...roughout Wisconsin, but they,re particularly focus...
Other Biology Technology:What color is your CEO's parachute? 2What color is your CEO's parachute? 3What color is your CEO's parachute? 4Was the Telecom Act of 1996 a boon or bomb for U.S.? 2Was the Telecom Act of 1996 a boon or bomb for U.S.? 3Was the Telecom Act of 1996 a boon or bomb for U.S.? 4Was the Telecom Act of 1996 a boon or bomb for U.S.? 5John Bergman, co-founder of Guild Software 2John Bergman, co-founder of Guild Software 3
(Date:10/12/2008)...elease is also available in French . , Resear...and GlaxoSmithKline Inc. have identified two genet... astounding sevenfold increase the risk of male pa...t. 12 in the journal Nature Genetics. , About ...ldness by age 45. The condition,s social and econo...
(Date:10/12/2008)...ave a built-in weapon against HIV, but until recen... study published online by the journal Nature re...me known as APOBEC-3G and suggests new directions... every human cell. It is capable of stopping HIV a...us transcribes its RNA into viral DNA. , The stu...
(Date:10/10/2008)... for Special Surgery researchers have found that s...n who are suffering from pregnancy complications c...g to a study in mice. In this autoimmune syndrome,...ipids, the main components of cell membranes. This...issue of the Journal of Clinical Investigation t...
(Date:10/10/2008)...chers report on a previously unknown relationship ...f their mitochondria a cell,s energy makers. Stem ...eater capacity to differentiate and are more likel...his week in JBC, could lead to methods of enrichin...eutic use and may provide some insights into the r...
Breaking Biology News(10 mins):Researchers discover baldness gene: 1 in 7 men at risk 2Body's anti-HIV drug explained 2Statins may prevent miscarriages 2Statins may prevent miscarriages 3Toms of Maine Tooth Floss Earns American Dental Associations Seal of Acceptance 1187 1Toms of Maine Tooth Floss Earns American Dental Associations Seal of Acceptance 1187 2J D Power and Associates Reports 3A CIGNA HealthCare Recognized for Call Center Customer Satisfaction Excellence For a Second Consecutive Year 1184 1J D Power and Associates Reports 3A CIGNA HealthCare Recognized for Call Center Customer Satisfaction Excellence For a Second Consecutive Year 1184 2J D Power and Associates Reports 3A CIGNA HealthCare Recognized for Call Center Customer Satisfaction Excellence For a Second Consecutive Year 1184 3Verdict One Releases Directory of Board Certified Attorneys for Consumers 1181 1Verdict One Releases Directory of Board Certified Attorneys for Consumers 1181 2Total Site Solutions Selected to Provide Construction Management Services for Existing Pharmaceutical and Biotech Customer for Data Center Expansion P 562 1Total Site Solutions Selected to Provide Construction Management Services for Existing Pharmaceutical and Biotech Customer for Data Center Expansion P 562 2Total Site Solutions Selected to Provide Construction Management Services for Existing Pharmaceutical and Biotech Customer for Data Center Expansion P 562 3
...nsion in yeast have been identified by researchers...ically reducing calorie intake, or caloric restric...ncluding yeast, worms and rodents. Previous resear...on due to caloric restriction, but worms and yeast...gh diet, showing that some other genes must be at ...
...s nerve cells to trees -- some are short and bushy...ew branches coming out of one or two main trunks. ...ic disorders and Firestein,s quest is to discover ..., A new paper by Firestein and her colleagues at R...es the role of the protein snapin in nerve branch,...
...have found that gene expression in the brain can d...h different life histories. Their study indicates ...how differential expression in males who migrate f...ns versus those who do not leave the freshwater en... University, the University of Massachusetts and t...
...e biological trigger that gives rise to Van Buchem...that can cause blindness and deafness. The finding...and could lead to new treatments for osteoporosis ...eam from Lawrence Livermore and Lawrence Berkeley ... BioMedical Research in Switzerland, and the DOE J...
Other Biology News:Snapin: A protein with therapy potential for autism 2Divergent life history shapes gene expression in brains of salmon 2Researchers track down cause of a disfiguring bone disorder 2Researchers track down cause of a disfiguring bone disorder 3
...madzu Biotech presents PsiPort Mass Directed Auto ... data acquisition system designed for automated co...ence and pharmaceutical discovery programs. The sy...gh throughput mass directed auto purification for ...
The Rapid DNA Ligation Kit enables ligation of sticky-end or blunt-end DNA fragments in just 5 min at 15-25 C. Depending on the DNA concentration, either circular (low DNA concentration) or concatem
Nuclease S7; Micrococcal nuclease from Roche Applied Science
Anti-VDAC (Voltage-Dependent Anion Channel) AVOID FREEZE/THAW CYCLES. Recognizes the porin 31HL protein. Corresponds to mAb 1 in the literature.
Biology Products: